505(b)(2) regulatory pathway

The 505(b)(2) regulatory pathway is a process for submitting a specific new drug application (NDA) with the Food and Drug Administration in the United States. It is designed for complex generic or biosimilar medications that can share historical public data from a drug that has been previously approved, therefore streamlining the regulatory review for a faster approval.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.